View Financial HealthAqua Bio Technology 配当と自社株買い配当金 基準チェック /06Aqua Bio Technology現在配当金を支払っていません。主要情報0%配当利回り-2.0%バイバック利回り総株主利回り-2.0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向0%最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesBoard Change • Aug 04No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Director Terje Blytt is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Jun 22No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Terje Blytt is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.New Risk • May 14New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.5m (US$821k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$821k). Market cap is less than US$10m (kr76.9m market cap, or US$8.39m).Board Change • May 11No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Terje Blytt is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Mar 21Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 388,240 Price\Range: NOK 5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 348,240 Price\Range: NOK 5 Transaction Features: Rights Offeringお知らせ • Feb 13Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 5 Transaction Features: Rights OfferingNew Risk • Dec 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (kr77.9m market cap, or US$7.69m).New Risk • Dec 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (kr79.0m market cap, or US$7.81m).Reported Earnings • Dec 01Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024).New Risk • Nov 30New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 1,462% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m. Market cap is less than US$10m (kr53.3m market cap, or US$5.27m). Minor Risk High level of debt (1,462% net debt to equity).お知らせ • Nov 22Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026.お知らせ • Nov 21+ 3 more updatesAqua Bio Technology ASA to Report Q3, 2025 Results on Nov 26, 2025Aqua Bio Technology ASA announced that they will report Q3, 2025 results on Nov 26, 2025New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr32m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 73% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (kr85.9m market cap, or US$8.54m).お知らせ • May 22Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, Cover Brands As. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.お知らせ • May 21Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, 3D Innovation Nordic AS. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.お知らせ • Apr 09Aqua Bio Technology Asa Announces Board ChangesAqua Bio Technology ASA at the extraordinary general meeting held on 9 April 2025, Roger Sedal is elected as new Chairman of the Board of Directors. Jan Pettersson shall resign from the Board of Directors. Following this, the Board of Directors shall consist of: Roger Sedal, Chairman; Lena Aas Varming, Director; Sofie Aimee Siem, Director; David Huggins, Director; Terje Blytt, Director; Jon Olav Ødegård, Observer.お知らせ • Apr 04Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,111,975 Price\Range: NOK 0.5 Transaction Features: Rights Offeringお知らせ • Mar 13Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million. Security Name: Shares Security Type: Common Stock Securities Offered: 48,432,000 Price\Range: NOK 0.5 Transaction Features: Subsequent Direct ListingNew Risk • Mar 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr80.1m (US$7.43m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (30% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Market cap is less than US$10m (kr80.1m market cap, or US$7.43m).お知らせ • Feb 26+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025Aqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025.お知らせ • Feb 12Aqua Bio Technology ASA Provides Earnings Guidance for the Fiscal Year 2025Aqua Bio Technology ASA provided earnings guidance for the fiscal year 2025. For the period, consolidated revenue is expected to exceed NOK 500.0 million applying Norwegian Generally Accepted Accounting Principles (N-GAAP), indicating conservative revenue growth compared to pro forma revenue (based on N-GAAP) assuming all 2024 acquisitions were completed as of January 1, 2024.お知らせ • Jan 21Aqua Bio Technology Announces Resignation of Celine Maria Sedal from Board of DirectorsAqua Bio Technology ASA has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment.Board Change • Jan 09No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director David Huggins was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Dec 31New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr228.6m market cap, or US$20.2m).Board Change • Dec 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director David Huggins was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 22Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024Aqua Bio Technology ASA announced that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. Mr. Henriksen has since 2016 served as Commercial Director in Norengros. He has also 15 years in different start-ups prior to working within the sales and distribution industry. Håvard Lindstrøm started as CEO in 2021.お知らせ • Aug 29Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS.Aqua Bio Technology ASA (OB:ABTEC) entered into an agreement to acquire 3d Innovation Nordic As from Coc Invest AS on April 25, 2024. Pursuant to the Agreement, Aqua Bio Technology also agreed to acquire Printprofil AS and Check Please AS from Coc Invest AS. The combined consideration for both the transactions is NOK 40.4 million. Under the Agreement, the purchase price for the Acquisitions shall be settled in a combination of shares and cash, subject to certain conditions. NOK 5 million shares in ABT will be issued at a price of NOK 6 per share, with a 3-year lock up. The cash will be total NOK 15 million, divided into two installments, depending on the Target Group's (collectively Printprofil AS and Check Please AS (jointly with 3D Innovation) financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. As of 2023, 3d Innovation, Printprofil AS and Check Please had reported a EBIDTA of NOK 5 million and turnover of NOK 87.6 million, of which 3d Innovation had a turnover of NOK 73 million. The completion of the Acquisitions is subject to satisfactory due diligence and approval from ABT's board of directors. Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS on August 28, 2024. The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5 million new shares at subscription price of NOK 3.66 per share, equal to today's opening trading price of the Company's shares, with a 3-year lock up (the "Consideration Shares"). The cash component will in total be NOK 15 million, divided into two installments, depending on the Target Group's financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. The Company's board of directors will convene at a later date to formally issue the Consideration Shares. The Transaction has been completed making ABT the 100 % direct and indirect owner of the Printprofil AS and Check Please AS (jointly with 3D, the "Target Group").お知らせ • Apr 28+ 3 more updatesAqua Bio Technology ASA to Report Q4, 2024 Results on Feb 12, 2025Aqua Bio Technology ASA announced that they will report Q4, 2024 results on Feb 12, 2025Board Change • Feb 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Camilla Andersson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Feb 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Camilla Andersson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 30Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 12.457015 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 12.457015 million. Security Name: Shares Security Type: Common Stock Securities Offered: 2,491,403 Price\Range: NOK 5 Transaction Features: Subsequent Direct Listing決済の安定と成長配当データの取得安定した配当: 0I8Cの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 0I8Cの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Aqua Bio Technology 配当利回り対市場0I8C 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (0I8C)0%市場下位25% (GB)2.1%市場トップ25% (GB)5.4%業界平均 (Chemicals)3.7%アナリスト予想 (0I8C) (最長3年)n/a注目すべき配当: 0I8Cは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 0I8Cは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 0I8C UK市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: 0I8Cが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YGB 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/20 14:10終値2026/08/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aqua Bio Technology ASA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Tomas SkeivysNorne Securities AS
Board Change • Aug 04No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Director Terje Blytt is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Jun 22No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Terje Blytt is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
New Risk • May 14New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.5m (US$821k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$821k). Market cap is less than US$10m (kr76.9m market cap, or US$8.39m).
Board Change • May 11No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Terje Blytt is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Mar 21Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 388,240 Price\Range: NOK 5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 348,240 Price\Range: NOK 5 Transaction Features: Rights Offering
お知らせ • Feb 13Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 5 Transaction Features: Rights Offering
New Risk • Dec 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (kr77.9m market cap, or US$7.69m).
New Risk • Dec 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (kr79.0m market cap, or US$7.81m).
Reported Earnings • Dec 01Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024).
New Risk • Nov 30New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 1,462% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m. Market cap is less than US$10m (kr53.3m market cap, or US$5.27m). Minor Risk High level of debt (1,462% net debt to equity).
お知らせ • Nov 22Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026.
お知らせ • Nov 21+ 3 more updatesAqua Bio Technology ASA to Report Q3, 2025 Results on Nov 26, 2025Aqua Bio Technology ASA announced that they will report Q3, 2025 results on Nov 26, 2025
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr32m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 73% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (kr85.9m market cap, or US$8.54m).
お知らせ • May 22Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, Cover Brands As. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.
お知らせ • May 21Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, 3D Innovation Nordic AS. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.
お知らせ • Apr 09Aqua Bio Technology Asa Announces Board ChangesAqua Bio Technology ASA at the extraordinary general meeting held on 9 April 2025, Roger Sedal is elected as new Chairman of the Board of Directors. Jan Pettersson shall resign from the Board of Directors. Following this, the Board of Directors shall consist of: Roger Sedal, Chairman; Lena Aas Varming, Director; Sofie Aimee Siem, Director; David Huggins, Director; Terje Blytt, Director; Jon Olav Ødegård, Observer.
お知らせ • Apr 04Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,111,975 Price\Range: NOK 0.5 Transaction Features: Rights Offering
お知らせ • Mar 13Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million. Security Name: Shares Security Type: Common Stock Securities Offered: 48,432,000 Price\Range: NOK 0.5 Transaction Features: Subsequent Direct Listing
New Risk • Mar 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr80.1m (US$7.43m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (30% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Market cap is less than US$10m (kr80.1m market cap, or US$7.43m).
お知らせ • Feb 26+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025Aqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025.
お知らせ • Feb 12Aqua Bio Technology ASA Provides Earnings Guidance for the Fiscal Year 2025Aqua Bio Technology ASA provided earnings guidance for the fiscal year 2025. For the period, consolidated revenue is expected to exceed NOK 500.0 million applying Norwegian Generally Accepted Accounting Principles (N-GAAP), indicating conservative revenue growth compared to pro forma revenue (based on N-GAAP) assuming all 2024 acquisitions were completed as of January 1, 2024.
お知らせ • Jan 21Aqua Bio Technology Announces Resignation of Celine Maria Sedal from Board of DirectorsAqua Bio Technology ASA has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment.
Board Change • Jan 09No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director David Huggins was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Dec 31New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr228.6m market cap, or US$20.2m).
Board Change • Dec 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director David Huggins was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 22Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024Aqua Bio Technology ASA announced that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. Mr. Henriksen has since 2016 served as Commercial Director in Norengros. He has also 15 years in different start-ups prior to working within the sales and distribution industry. Håvard Lindstrøm started as CEO in 2021.
お知らせ • Aug 29Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS.Aqua Bio Technology ASA (OB:ABTEC) entered into an agreement to acquire 3d Innovation Nordic As from Coc Invest AS on April 25, 2024. Pursuant to the Agreement, Aqua Bio Technology also agreed to acquire Printprofil AS and Check Please AS from Coc Invest AS. The combined consideration for both the transactions is NOK 40.4 million. Under the Agreement, the purchase price for the Acquisitions shall be settled in a combination of shares and cash, subject to certain conditions. NOK 5 million shares in ABT will be issued at a price of NOK 6 per share, with a 3-year lock up. The cash will be total NOK 15 million, divided into two installments, depending on the Target Group's (collectively Printprofil AS and Check Please AS (jointly with 3D Innovation) financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. As of 2023, 3d Innovation, Printprofil AS and Check Please had reported a EBIDTA of NOK 5 million and turnover of NOK 87.6 million, of which 3d Innovation had a turnover of NOK 73 million. The completion of the Acquisitions is subject to satisfactory due diligence and approval from ABT's board of directors. Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS on August 28, 2024. The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5 million new shares at subscription price of NOK 3.66 per share, equal to today's opening trading price of the Company's shares, with a 3-year lock up (the "Consideration Shares"). The cash component will in total be NOK 15 million, divided into two installments, depending on the Target Group's financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. The Company's board of directors will convene at a later date to formally issue the Consideration Shares. The Transaction has been completed making ABT the 100 % direct and indirect owner of the Printprofil AS and Check Please AS (jointly with 3D, the "Target Group").
お知らせ • Apr 28+ 3 more updatesAqua Bio Technology ASA to Report Q4, 2024 Results on Feb 12, 2025Aqua Bio Technology ASA announced that they will report Q4, 2024 results on Feb 12, 2025
Board Change • Feb 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Camilla Andersson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Feb 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Camilla Andersson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 30Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 12.457015 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 12.457015 million. Security Name: Shares Security Type: Common Stock Securities Offered: 2,491,403 Price\Range: NOK 5 Transaction Features: Subsequent Direct Listing